BVF Inc. IL Grows Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX)

BVF Inc. IL lifted its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 7.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,036,679 shares of the company's stock after acquiring an additional 69,679 shares during the period. BVF Inc. IL owned approximately 9.98% of Avalo Therapeutics worth $7,703,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in shares of Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after buying an additional 3,754 shares during the last quarter. Marshall Wace LLP purchased a new stake in Avalo Therapeutics during the 4th quarter valued at about $114,000. Walleye Capital LLC acquired a new position in shares of Avalo Therapeutics in the fourth quarter valued at about $145,000. Northern Trust Corp purchased a new position in shares of Avalo Therapeutics in the fourth quarter worth about $168,000. Finally, Bank of Montreal Can acquired a new stake in shares of Avalo Therapeutics during the fourth quarter worth about $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AVTX has been the subject of a number of recent research reports. Wedbush reissued an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler began coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an "overweight" rating and a $48.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a "buy" rating and a $36.00 price target on the stock. Jefferies Financial Group assumed coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They set a "buy" rating and a $23.00 price objective for the company. Finally, HC Wainwright restated a "neutral" rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $33.00.

Avalo Therapeutics Stock Down 5.3 %

AVTX traded down $0.23 during trading on Friday, hitting $4.12. The company's stock had a trading volume of 30,841 shares, compared to its average volume of 52,952. Avalo Therapeutics, Inc. has a twelve month low of $4.12 and a twelve month high of $16.00. The business's fifty day simple moving average is $6.20 and its 200 day simple moving average is $8.21.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.